Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 203


Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.

Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, Fiorentino M.

Diagn Mol Pathol. 2008 Dec;17(4):220-6. doi: 10.1097/PDM.0b013e318161f993.


Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.


Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C.

J Clin Oncol. 2008 Apr 1;26(10):1642-9. doi: 10.1200/JCO.2007.11.6699.


HER2 status and benefit from adjuvant trastuzumab in breast cancer.

Paik S, Kim C, Wolmark N.

N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. No abstract available.


Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.


Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.


The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.

Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ.

Am J Clin Pathol. 2008 Mar;129(3):383-90. doi: 10.1309/KFKDNK8CENVN24VU.


HER-2 and topoisomerase II as predictors of response to chemotherapy.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.

J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. Review.


National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.

Vani K, Sompuram SR, Fitzgibbons P, Bogen SA.

Arch Pathol Lab Med. 2008 Feb;132(2):211-6. doi: 10.1043/1543-2165(2008)132[211:NHPTRU]2.0.CO;2.


Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.


Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.

J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28.


Heterogeneity of breast cancer and implications of adjuvant chemotherapy.

Razzak AR, Lin NU, Winer EP.

Breast Cancer. 2008;15(1):31-4. doi: 10.1007/s12282-007-0007-y.


HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

Hicks DG, Kulkarni S.

Am J Clin Pathol. 2008 Feb;129(2):263-73. doi: 10.1309/99AE032R9FM8WND1. Review.


Triple negative breast cancer: current understanding of biology and treatment options.

Kang SP, Martel M, Harris LN.

Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6. doi: 10.1097/GCO.0b013e3282f40de9. Review.


A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE.

Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.


HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne].


Molecular subtypes in breast cancer evaluation and management: divide and conquer.

Peppercorn J, Perou CM, Carey LA.

Cancer Invest. 2008 Feb;26(1):1-10. doi: 10.1080/07357900701784238. Review. No abstract available.


HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P.

J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. Epub 2007 Dec 25.


Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.


Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Dec 1;25(34):5418-25.

Items per page

Supplemental Content

Write to the Help Desk